104  0 Kommentare Oncodesign Precision Medicine (OPM) Announces its IPO Through Direct Listing on Euronext Access + Paris

This listing will enable OPM, which was created from the transfer of Oncodesign SA's Biotech and AI assets, to work on the identification and validation of targets, as well as the development of molecules, against resistant and metastatic cancers. OPM is completely independent of Oncodesign SA.

Details of the operation

• ISIN code: FR001400CM63
• Mnemonic: MLOPM
• Listing place: Euronext Paris
• Market: Euronext Access +
• Number of shares: 6 851 417
• Date of first listing: 5 October 2022
• Reference price of the share on 5 October 2022 at the opening of the markets: €0.817

As a reminder, each Oncodesign shareholder will receive one OPM share for one Oncodesign share held at the close of trading on 4 October 2022. No new shares will be issued in connection with the admission of OPM shares to Euronext Access+.

On 26 September 2022, Euronext Paris S.A. authorized the listing of OPM's ordinary shares on Euronext Access + Paris under the direct listing procedure in connection with the allocation of OPM shares to Oncodesign shareholders.

Lesen Sie auch

Gewinn, Umsatz über Erwartung

Novartis hebt Prognosen an: Starke Medikamentenverkäufe treiben Wachstum

gestern 08:18

Verlierer des Tages

Sartorius-Aktie tiefrot: "Weiteres Abwärtspotenzial"

18.04.24, 12:00

100 Megawatt

JinkoSolar erhält Großauftrag – Aktie legt kräftig zu

vor 6 Minuten

Turnaround vor dem Abschluss

Mit dieser Aktie an steigenden Kupfer-, und Nickelpreisen partizipieren!

vor 34 Minuten

A summary of the tax consequences that may apply to Oncodesign shareholders resident in France as a result of the distribution is set out in paragraph 21.8 of the information document (only in French) prepared by OPM in the context of its listing on Euronext Access + Paris.

Shareholders should check with their usual tax advisor as to the tax treatment of their particular case. Persons who do not have their tax residence in France must also comply with tax legislation in force in their country of residence.

Distribution of OPM's capital

OPM has the same shareholder base as Oncodesign except for (i) the 22,383 treasury shares held by Oncodesign and the 81 fractional shares not distributed by Oncodesign, which will be transferred to the Company, and (ii) the 2,924 shares held by Oncodesign that were transferred to P.C.G. and that result from the share capital before the Contribution. Thus, based on the current share capital of Oncodesign and the elements indicated above, the distribution of the Company's share capital will be as follows: